Myokardia therapeutics
WebMay 11, 2024 · BRISBANE, Calif., May 11, 2024 (GLOBE NEWSWIRE) -- MyoKardia, Inc. ( MYOK) today announced positive topline data from the company’s Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for... WebJul 21, 2024 · MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven …
Myokardia therapeutics
Did you know?
WebResilience is a technology company dedicated to broadening access to complex medicines and to protecting biopharmaceutical supply chains against disruption. We’re building a … WebOct 22, 2024 · Bristol Myers Squibb, a global biopharmaceutical company, recently announced the aquisition of MyoKardia, a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, for $13.1 billion in cash. MyoKardia was co-founded by Leslie Leinwand, …
WebMay 5, 2024 · That biotech successfully developed a drug for a genetic form of heart disease using a clinical trial that enrolled only 250 patients to test the treatment's … WebOct 5, 2024 · MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction ...
WebJan 2, 2024 · Acer Therapeutics, headquartered in Newton, Mass., in-licensed osanetant, a clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist from Paris-based Sanofi. ... In related news, MyoKardia announced it had regained global rights to all the programs it had inked with Sanofi. The research deal ended on December 31, 2024, and … Web" MyoKardia’s scientists have discovered a portfolio of small molecule therapeutics aimed at the muscle proteins of the heart and intended to correct the excessive contraction, impaired relaxation or insufficient contraction underlying diseases of systolic and diastolic dysfunction. We are applying a precision medicine approach to develop our ...
WebNov 16, 2024 · MYOKARDIA, INC. : Shareholders Board Members Managers and Company Profile US62857M1053 MarketScreener Homepage Equities United States Nasdaq MyoKardia, Inc. Company MYOK US62857M1053 MYOKARDIA, INC. (MYOK) Add to my list Summary Charts News Company Funds
WebMay 15, 2024 · MyoKardia is developing mavacamten for the treatment of conditions in which excessive cardiac contractility and impaired diastolic filling of the heart are the underlying cause. Mavacamten is initially being developed for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM). chrome big5WebMyoKardia is developing a pipeline of novel, small molecule therapeutics that address key clinical needs for patients with genetic heart disease. … chrome bicycle basketWebDr. June Lee was most recently Founder and CEO of Esker Therapeutics. Previously, she served as Chief Development Officer and Chief Operating Officer of MyoKardia, Inc., where she built and led a world-class development organization culminating in the company’s $13.1 billion acquisition by Bristol Myers Squibb. g-homa timers for electrical outletsWebJul 18, 2024 · MyoKardia now anticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2024, ahead of previous guidance of the second half of 2024. ... MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlie ... chrome big comWebJul 7, 2024 · MyoKardia’s investigational drug danicamtiv is intended to increase heart contractions without interfering with the heart’s ability to fill. The company recently … chrome big ripperWebEnliven Therapeutics, Inc.于2024年6月在特拉华州注册成立。Enliven是一家临床阶段的生物制药公司，专注于发现和开发小分子抑制剂，帮助癌症患者不仅活得更长，而且活得更好。 Enliven的目标是通过一种精确的肿瘤学方法来解决现有的和新出现的未满足的需求，从而 ... chrome bifold door hingesWebOct 28, 2024 · MyoKardia plans to advance MYK-491 into a Phase 2 clinical trial in DCM patients with certain genetic mutations of the cardiac sarcomere in the first half of 2024 and continues to evaluate additional targeted patient populations for potential development. ... MyoKardia’s initial focus is on the development of small molecule therapeutics aimed ... chrome bigpicture popup